表紙
市場調查報告書

乾癬治療藥的藥價·醫療費償付·取用

Psoriasis Pricing, Reimbursement, and Access

出版商 Datamonitor Healthcare 商品編碼 911287
出版日期 內容資訊 英文 96 Pages
商品交期: 最快1-2個工作天內
價格
乾癬治療藥的藥價·醫療費償付·取用 Psoriasis Pricing, Reimbursement, and Access
出版日期: 2019年03月28日內容資訊: 英文 96 Pages
簡介

本報告提供全球乾癬治療藥市場相關調查,彙整市場概要,法規環境,取用促進因素,證據和等級,各國市場考察·建議等資料。

概要

法規標籤

  • 美國,市場上市售的乾癬治療藥日本,及EU主要5個國家
  • 參考資料

全球取用促進因素

  • 乾癬生技藥品的支出是保險者特別關注的問題
  • 生技藥品的高額藥價導致進入壁壘和提供折扣的壓力
  • 付款人使用招標,醫生獎勵和處方排除來推動生物仿製藥的使用

證據和價值

  • 付款人和醫生認為PASI和DLQI是最重要的指標
  • 基於PASI或DLQI區分新代理的範圍有限
  • 提供治療的假期或無藥物緩解可以區分未來的開發平台治療、其他

近幾年核準的醫藥品·開發平台藥物的取用

  • IL-17和IL-23抑製劑被認為是更有效的藥物,但TNF-α抑製劑仍將是一線生物製劑
  • IL-23藥物顯示出令人印象深刻的功效,但與IL-17s相比難以獲得首選通路
  • 付款人計劃通過本地或區域性折扣或合同來利用白介素領域日益激烈的競爭、其他

藥價

美國

加拿大

日本

法國

德國

義大利

西班牙

英國

調查手法

目錄

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

TABLE OF CONTENTS

OVERVIEW

REGULATORY LABELS

  • Marketed psoriasis products in the US, Japan, and five major EU markets
  • Bibliography

GLOBAL ACCESS LEVERS

  • Spend on psoriasis biologics is a particular concern for payers
  • High prices of biologics are leading to access barriers and pressure to offer discounts
  • Payers use tenders, physician incentives, and formulary exclusions to drive biosimilar uptake
  • Payers prefer straight discounts to outcomes-based risk agreements

EVIDENCE AND VALUE

  • Payers and physicians regard PASI and DLQI as the most important endpoints
  • Limited scope for differentiation of new agents based on PASI or DLQI
  • Providing treatment holidays or drug-free remissions could differentiate future pipeline treatments
  • Head-to-head trials with active comparators are critical in establishing differentiation
  • Minimum efficacy data of six months needed for good formulary access
  • Six-monthly or annual maintenance dosing regimens may be advantageous for pipeline agents
  • Cardioprotective effect of interleukins remains speculative, but data are welcome
  • Real-world evidence could be used to bolster local or regional positioning in the treatment algorithm

ACCESS TO RECENTLY APPROVED AND PIPELINE DRUGS

  • IL-17 and IL-23 inhibitors are viewed as more efficacious drugs, but TNF-alpha inhibitors will remain first-line biologics
  • IL-23 agents exhibit impressive efficacy but struggle to achieve preferred access versus IL-17s
  • Payers plan to leverage growing competition in the interleukin space through local or regional discounts or contracts
  • Tremfya's superiority results against Cosentyx will drive prescribing but not pricing or formulary access
  • Siliq's prospects remain poor, despite no correlation to suicide
  • Dosing frequency is not an important point of differentiation
  • Weaker PASI scores dampen Ilumya's access prospects
  • Risankizumab's strong efficacy data boost access prospects, but there is limited scope for a price premium
  • Moderate appetite for an oral inhibitor competitor to Otezla in psoriasis

PRICING

US

  • Insights and strategic recommendations

CANADA

  • Insights and strategic recommendations

JAPAN

  • Insights and strategic recommendations
  • Japan's pricing strategy is reliant on pricing premiums for innovative medicines
  • Bibliography

FRANCE

  • Insights and strategic recommendations
  • ASMR rating has an impact on pricing
  • Bibliography

GERMANY

  • Insights and strategic recommendations
  • Positive assessment from the G-BA will impact price negotiations
  • Bibliography

ITALY

  • Insights and strategic recommendations
  • Bibliography

SPAIN

  • Insights and strategic recommendations
  • National reimbursement decisions are not a major access barrier in Spain
  • Regional access to psoriasis medicines varies in Spain
  • Bibliography

UK

  • Insights and strategic recommendations
  • NICE approval is a key market access barrier
  • Bibliography

METHODOLOGY

  • Primary research
  • Price assumptions
  • Exchange rates
  • Bibliography

LIST OF FIGURES

  • Figure 1: Price sources and calculations for the US and EU, by country

LIST OF TABLES

  • Table 1: Marketed products and approved indications for psoriasis in the US, Japan, and five major EU markets
  • Table 2: Biosimilar access levers in the US and five major EU markets
  • Table 3: Levers impacting access to psoriasis drugs in the US and five major EU markets
  • Table 4: Summary of important key endpoints in psoriasis clinical trial design
  • Table 5: National reimbursement decisions for marketed and assessed Ils
  • Table 6: Contracting and financial agreements for interleukins
  • Table 7: Likely reimbursement for Ilumya in psoriasis
  • Table 8: Likely reimbursement for risankizumab in psoriasis
  • Table 9: Pricing of key psoriasis drugs in the US, Japan, and five major EU markets, by country, 2019
  • Table 10: Pricing premiums given to medicines in Japan that can demonstrate benefit over comparators
  • Table 11: Transparency Committee's ASMR ratings and pricing implications
  • Table 12: Transparency Committee's SMR ratings and pricing implications
  • Table 13: Spanish Society of Hospital Pharmacy ratings
  • Table 14: Exchange rates used for calculating drug prices